About the Chronic Obstructive Pulmonary Disease (COPD) Drugs Market in China
Chronic obstructive pulmonary disease (COPD) is a broad term that covers progressive lung diseases, including emphysema, chronic bronchitis, refractory (non-reversible) asthma, and some forms of bronchiectasis. It restricts airflow in the lungs and is characterized by diffculty breathing. The exact etiology of COPD is not understood, but most cases are caused due to genetic factors and by inhaling pollutants, including smoke, fumes, and chemicals. As the disease develops, the symptoms tend to get worse and damages the lungs. The disease cannot be cured, and can only be managed and treated.The COPD drugs market in China is under penetrated. It is dominated by fixed dose combinations of LABA/ICS. Air pollution is the major contributing factor for the growing prevalence of the disease. Nearly 10% of the population in the region who are over the age of 40 years has COPD. The disease is expected to become one of the leading causes of death in the country by 2020. Lack of awareness about the disease and its treatment options affects the growth of the market in this region.
Technavio’s analysts forecast the chronic obstructive pulmonary disease drugs market in China to grow at a CAGR of 15.56% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the chronic obstructive pulmonary disease drugs market in China for 2016-2020. To calculate the market size, Technavio considers the revenue generated from the total consumption of the chronic obstructive pulmonary disease drugs globally. The report does not include revenue generated from the aftermarket service of the product.
The market is divided into the following segments based on drug class:
Technavio Announces the Publication of its Research Report – COPD Drugs Market in China 2016-2020
Technavio recognizes the following companies as the key players in the COPD drugs market in China: AstraZeneca, Boehringer Ingelheim, GSK, Merck, and Novartis.
Other Prominent Vendors in the market are: Ache Laboratorios Farmaceuticos, Almirall, Aquinox Pharmaceuticals, Ario Pharma, BioMarck Pharmaceuticals, Gilead Sciences, Mereo BioPharma Group, Mylan, Orion, Pearl Therapeutics, Prosonix, Teva Pharmaceutical Industry, Theravance Biopharma, Theron Pharmaceuticals, Verona Pharma, Xention, and ZAI Lab.
Commenting on the report, an analyst from Technavio’s team said: “A key trend which is boosting market growth is the increased focus on combination therapies. Combination therapies have a better advantage over monotherapies in providing better efficacy in the treatment of a condition. Manufacturers are now concentrating on developing combination therapies to treat COPD.These combination therapies reduce COPD-related hospitalizations and bring out better treatment outcomes in patients. Thus, the development of combinations therapies will increase the patient compliance toward the uptake of medications and help in the growth of the market.”
According to the report, pollutants such as ground-level ozone, carbon dioxide, smog, fumes from vehicles, and particulates such as dust, soot, and pollen grains are known to trigger diseases such as COPD, asthma, bronchitis, and other respiratory issues. Airborne particles, sulfur dioxide, and nitrogen oxide are critical environment pollutants that worsen respiratory symptoms. Rapid globalization, urbanization, and industrialization have led to the rise in environmental pollution, which has increased the prevalence of COPD.
Further, the report states that a major factor that could hamper market growth is the low diagnosis rate of COPD. It is difficult for physicians to recognize COPD at an early stage as the first symptoms of the disease include common problems such as a cough, sputum production, and shortness of breath. Thus, the diagnosis rate is only about one-third of the prevalent cases. This low diagnosis of COPD can be attributed to the lack of physician’s awareness about the risk factors, symptoms, and biomarkers of the disease.
AstraZeneca, Boehringer Ingelheim, GSK, Merck, Novartis, Ache Laboratorios Farmaceuticos, Almirall, Aquinox Pharmaceuticals, Ario Pharma, BioMarck Pharmaceuticals, Gilead Sciences, Mereo BioPharma Group, Mylan, Orion, Pearl Therapeutics, Prosonix, Teva Pharmaceutical Industry, Theravance Biopharma, Theron Pharmaceuticals, Verona Pharma, Xention, and ZAI Lab.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook